Navigation Links
Dr. Steven Hughes Joins Medical Ceramics Provider: C5 Medical Werks
Date:1/7/2009

Medical ceramic company strengthens global team

DENVER, Jan. 7 /PRNewswire/ -- C5 Medical Werks, a subsidiary of the largest manufacturer of technical ceramics in North America, announced today that Dr. Steven Hughes has joined the company as Sales Manager for Orthopaedic and Medical Devices.

Steven will spearhead the business development and technical support functions for C5 Medical Werks in Europe and Latin America in addition to supporting new product development on a global level for C5.

The Company has experienced a high level of growth over previous years and has a very strong and robust order book going into 2009. With state-of-the-art ceramics manufacturing in North America and strong technical support in both North America and Europe, C5 Medical Werks is very well positioned to drive sustained growth for medical companies who require "best in class" quality systems.

With a strong commitment to quality and rapid response, C5 Medical Werks is a major supplier of medical ceramic components to: Orthopaedic, Spinal, Dental, Electro-implantable, Brachytherapy and other medical device manufacturers.

"We are delighted that Dr. Steven Hughes has joined our team at C5 and I believe this shows our commitment to supporting our customers with high caliber personnel as we continue to grow our business," said Andrew Nield, Director of Sales and Marketing for C5 Medical Werks. "Steven's experience in orthopaedics, medical devices, and advanced ceramics coupled with his international business experience will make him a huge asset to our organization as we grow our medical business world-wide."

About C5 Medical Werks

C5 Medical Werks is a wholly owned subsidiary of CoorsTek, the largest manufacturer of technical ceramics in North America, and is a leading provider of ceramic solutions for the medical device industry. The Company manufactures medical gr
'/>"/>

SOURCE C5 Medical Werks
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Stevens Health, Technology and Society roundtable: Sept. 19
2. Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer
3. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
4. Stevens UV expert at Science-on-Saturday program
5. Northwestern Memorial Hospitals Steven J. Stryker MD Unveils Campaign With Empower Public Relations
6. Stevens chemists identify compounds to lure nutria, a rat-like pest ravaging Gulf Coast wetlands
7. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
8. Weight Watchers Names Steven C. McCormick as President, North America
9. Norma Smith and Dr. Steven A. Stuchin honored at 2008 Founders Gala for NYU Hospital for Joint Diseases
10. MHS Announces Departure of Dr. Steven Friedman; Search for New Executive Director
11. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2009)...ngsters with the disease , , THURSDAY, J...betes are more likely to be overweight than those ...ous health complications, researchers say. , Th...weight problems faced by U.S. youngsters with type...t usually shows up in childhood or in young adults...
(Date:7/2/2009)...itis B virus (HBV) are associated with the develop...tients with HBV infections are at increased risk o...in the Journal of the National Cancer Institute ,...nown cause of hepatocellular carcinoma (HCC), the ... have looked at whether patients with specific mut...
(Date:7/2/2009)...y night saw the launch of (RED)ZONES at the first ...d off their new tour to a rapturous sold out crowd...tion areas directly adjacent to the stage which wi... for the (RED)ZONES are available through auction ...to the Global Fund to help fund AIDS programs in A...
(Date:7/2/2009)...hytherapy and remain free of disease for five year...10 years, according to a study in the July 1 issue...gy*Biology*Physics , the official journal of the A...Brachytherapy is the placement of radioactive sour...or temporarily, depending upon the cancer. , In t...
Breaking Medicine News(10 mins):Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3
...lecular Biology Laboratory (EMBL) and the Universi...s us against a serious kidney disease In the cur...hat mutations in the gene cause nephronopthisis (N...ase marked by kidney degeneration during childhood...
...n died from metal poisoning last year after ingest...e, the B.C. Coroners Service confirmed Thursday A ...buying drugs over the Internet after the death of ...nfirm the pills appear to have killed 57-year-old ...
...would have to consider a radical change in their l...and greener future, a report prepared by the Centr...cording to the report, the lifestyle changes could...ning battery- operated cars and avoiding affordabl...
...pound from olive-pomace oil slows down the spread ... Granada and Hospital Carlos III in Madrid, establ...skin, inhibits serin-protease, the enzyme used by ...ected cell into the extra cellular environment and...
Other Medicine News:Health News:New Therapies for Kidney Diseases 2Health News:Online Counterfeit Pills Kills Woman 2Health News:Radical Change in the Lifestyle Might Bring a Greener Future for Brits 2
(Date:6/25/2009)...OX(R) and EMBEDA (TM) Data Highlighted at the Coll..., , RENO, Nev., June 25 King ...d that the Company is presenting safety and effica...wo novel opioid analgesic formulations that are in...llege on Problems of Drug Dependence. King is als...
(Date:6/24/2009)...LEUVEN, Belgium, June 25 ..., Lead Product for the,Non-Surgical Treatment of ... ThromboGenics NV (Euronext Brussels: THR), a bio...evelopment of innovative treatments for eye,disea...hat its lead product,microplasmin, which is in Ph...
(Date:6/24/2009)...iminary top-line results of second Phase III study...igue and improved daily function in fibromyalgia p...II study , , PALO ALTO, Calif., and BRUSSELS, J...egulated information -- Jazz Pharmaceuticals, Inc...B) announced today positive preliminary top-line r...
(Date:6/24/2009)...TLE, June 24 A Common... Cooperative is structured with incentives align... ways that make the most sense operationally and c...rofiles looking at medical systems that have the a...necessary for a high performing health care system...
Breaking Medicine Technology:King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 6Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Prism glasses expand the view for patients with hemianopia 19103 1Prism glasses expand the view for patients with hemianopia 19103 2Prism glasses expand the view for patients with hemianopia 19103 3Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 1Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 2Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 3Hospital Association Moves Headquarters to Downtown Austin 19097 1Hospital Association Moves Headquarters to Downtown Austin 19097 2Independence Blue Cross Supports 2008 Senior Games 19094 1Independence Blue Cross Supports 2008 Senior Games 19094 2
...SS WIRE)--Apr 14, 2007 - In a late-breaker,present...ssociation,for the Study of the Liver (EASL), rese...m analysis of the PROVE 1 clinical trial,which is...y with,the investigational hepatitis C protease in...th pegylated interferon (peg-IFN) and,ribavirin (R...
...ted Phase 2 Study Now Underway at Nine,Centers, SA...regene,Inc., a biopharmaceutical company, today p...linical trial of CERE-120, a gene,therapy product ...sease, demonstrating a 36 percent (p<0.001) reduct...inistration, as measured,by the Unified Parkinson,...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 2Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 3Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 4
The dual lumen M.R.I. model is available with 1.0 or 1.2 mm inner diameter catheters (each lumen). ,Dual oval lumen catheters offer larger lumen equivalency while maintaining maximum catheter strengt
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe
...nect to the CoolGard 3000 Thermal Regulation Syste...re input by the user. It remotely senses changes i...ts the temperature of the circulating saline withi...enance of temperature. The CoolGard 3000 represent...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: